Thyroxine is one of 69 small molecule programs targeting Severe Acute Respiratory Syndrome. It is currently in Phase 2.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
150 competitors in Type 2 Diabetes Mellitus
DWP16001
Maridebart Cafraglutide
Retatrutide
Elecoglipron
Imeglimin
Ganagliflozin
Dorzagliatin
Adenocard
NOVOLIN R
Thyroxine
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details